We reiterate BUY and raise our target price (TP) by 8% thanks to a 4% increase in our aggregate 2022F-2023F NPAT-MI that is driven by our higher projections for MCH, WCM and TCB. In addition, we roll over our TP to YE2022. 

Powered by Froala Editor